iBio, Inc.
IBIONASDAQHealthcare● Active
$1.73
$-0.09(-4.95%)
Market Cap$27315788
P/E Ratio—
52W High$3.82
52W Low$0.56
iBio, Inc. (IBIO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IBIO · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.07
Est. -$0.06 · -16.7%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▼ Miss EPS
IBIO reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Sep 29, 2026 | -$0.06 | — | — | — | $0.00B | — |
| ◌ Q3 FY2026 | Sep 4, 2026 | -$0.07 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 12, 2026 | -$0.06 | -$0.07 | -16.7% | — | $0.00B | — |
| ▼ Q1 FY2026 | Feb 10, 2026 | -$0.08 | -$0.09 | -12.5% | — | $0.00B | — |
| ▼ Q4 FY2025 | Nov 12, 2025 | -$0.07 | -$0.11 | -57.1% | $0.00B | $0.00B | +200.0% |
| ▲ Q3 FY2025 | Sep 5, 2025 | -$0.39 | -$0.31 | +20.5% | $0.00B | $0.00B | +100.0% |
| ▼ Q2 FY2025 | May 2, 2025 | -$0.39 | -$0.49 | -25.6% | — | $0.00B | — |
| ▼ Q1 FY2025 | Feb 10, 2025 | -$0.45 | -$0.48 | -6.7% | $0.00B | — | — |
Q3 FY2026
Sep 29, 2026
EPS Actual
—
EPS Est.
-$0.06
EPS Surpr.
—
Revenue
—
Q3 FY2026
Sep 4, 2026
EPS Actual
—
EPS Est.
-$0.07
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Miss
EPS Actual
-$0.07
EPS Est.
-$0.06
EPS Surpr.
-16.7%
Revenue
—
Q1 FY2026
Feb 10, 2026Miss
EPS Actual
-$0.09
EPS Est.
-$0.08
EPS Surpr.
-12.5%
Revenue
—
Q4 FY2025
Nov 12, 2025Miss
EPS Actual
-$0.11
EPS Est.
-$0.07
EPS Surpr.
-57.1%
Revenue
$0.00B
Q3 FY2025
Sep 5, 2025Beat
EPS Actual
-$0.31
EPS Est.
-$0.39
EPS Surpr.
+20.5%
Revenue
$0.00B
Q2 FY2025
May 2, 2025Miss
EPS Actual
-$0.49
EPS Est.
-$0.39
EPS Surpr.
-25.6%
Revenue
—
Q1 FY2025
Feb 10, 2025Miss
EPS Actual
-$0.48
EPS Est.
-$0.45
EPS Surpr.
-6.7%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2027 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Q1 FY2027 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Q4 FY2026 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Q3 FY2026 | $-0.07 | $-0.07 | $-0.06 | 2 |
| Q2 FY2026 | $-0.08 | $-0.06 | $-0.05 | 4 |
| Q1 FY2026 | $-0.07 | $-0.06 | $-0.04 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 12, 2026 | -16.7% | $1.66 | $1.61 | -3.01% |
| ▼ Q1 FY2026 | Feb 10, 2026 | -12.5% | $2.41 | $2.27 | -5.81% |
| ▼ Q4 FY2025 | Nov 12, 2025 | -57.1% | $1.24 | $1.25 | +0.81% |
| ▲ Q3 FY2025 | Sep 5, 2025 | +20.5% | $0.81 | $0.84 | +2.92% |
| ▼ Q2 FY2025 | May 2, 2025 | -25.6% | $1.03 | $1.01 | -1.94% |
| ▼ Q1 FY2025 | Feb 10, 2025 | -6.7% | $3.72 | $3.42 | -8.06% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +0.0% | $2.56 | $2.55 | -0.39% |
| ▼ Q3 FY2024 | Sep 25, 2024 | -93.6% | $1.83 | $1.82 | -0.55% |
Q2 FY2026-3.01%
Report Date
May 12, 2026
EPS Beat/Miss
-16.7%
Price Before
$1.66
Price After
$1.61
Q1 FY2026-5.81%
Report Date
Feb 10, 2026
EPS Beat/Miss
-12.5%
Price Before
$2.41
Price After
$2.27
Q4 FY2025+0.81%
Report Date
Nov 12, 2025
EPS Beat/Miss
-57.1%
Price Before
$1.24
Price After
$1.25
Q3 FY2025+2.92%
Report Date
Sep 5, 2025
EPS Beat/Miss
+20.5%
Price Before
$0.81
Price After
$0.84
Q2 FY2025-1.94%
Report Date
May 2, 2025
EPS Beat/Miss
-25.6%
Price Before
$1.03
Price After
$1.01
Q1 FY2025-8.06%
Report Date
Feb 10, 2025
EPS Beat/Miss
-6.7%
Price Before
$3.72
Price After
$3.42
Q4 FY2024-0.39%
Report Date
Nov 12, 2024
EPS Beat/Miss
+0.0%
Price Before
$2.56
Price After
$2.55
Q3 FY2024-0.55%
Report Date
Sep 25, 2024
EPS Beat/Miss
-93.6%
Price Before
$1.83
Price After
$1.82
Avg Beat Reaction+1.26%
Avg Miss Reaction-3.09%
Beat Rate2 / 8 quarters
Largest Move-8.06% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IBIO ends December
iBio, Inc. (IBIO) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.07 — missing the analyst consensus of $-0.06 by -16.7%. The next IBIO earnings date is expected around September 1, 2026.
Each quarter, investors track IBIO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IBIO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IBIO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IBIO earnings · 5 questionsiBio, Inc.'s next earnings report is expected around September 1, 2026. IBIO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IBIO historically reports after market close (AMC).
IBIO earnings datewhen is IBIO earningsIBIO next earnings datewhen does IBIO report earningsIBIO earnings calendar
▸ Source: FMP · iBio, Inc. SEC filings · US GAAP · iBio, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026